Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Two completely different types of success rates
No?
Wow !
Patience And
Perspective
$AVXL
And for years Anavex has continued to defy the odds... setting up quite nicely in my opinion.
Added some under 4$ today...
Have a GUT feeling we won’t see these prices ever again...
Jmho
Good luck everyone $AVXL
Interesting science
$Kala
Well said
Agree 100%
Short term
Headed back to <~ $1,000
Long term
I bet we see >~ $3,000 by 2022
Jmho of course
I agree
Albeit.. Huge risk
As long and the science remains steady .. it’s a gamble I’m willing to take.
Agreed
All signs seem to point to Anavex having some extreme confidence in their endeavors to continue these pursuits without outside help/influence.
Only time will tell why/if these routes were taken for the better.
I personally believe Dr.M truly appreciates the full potential here.
... and is determined
to maximize investor returns
as well as patient/caregiver benefits.
Nobody is perfect.
“TGD” could definitely use some improvement on certain aesthetics (NO, not the hair. The hair is perfect as is)
... but
I see NO issues when it comes to the way he is building the hardware to this Anavex machine.
I am also quite excited to see how 3-71 fares as well...
Quite an impressive pipeline.
It’s been many years already... but the true beginning Is likely yet to come.
All Jmho of course
The science is, or isn’t, what it is.
... A noble gamble of one’s time, money etc, in my opinion.
Good luck everyone $AVXL
Patience And
Perspective
What an amazing opportunity presented here today...
Jmho
Good luck everyone $AVXL
Patience And
Perspective
What isn’t clear regarding the PR?
Anavex can’t afford to act like that ... learned from the past.
They will let the science speak for itself.
Got it in the mail today..
thanks
$ivitf
Great future here imo
But.. short term
Back to 1200?
Either way
I wouldn’t be surprised to see over 2k next year.. Easy.
Jmho
$tsla
A material event occurred.. PR.
Oh ok. Didn’t know that. Adding duct tape to my shopping list. Thanks.
That type of thinking wasn’t my intention but I see how it came off that way.
Efficacy was not my intended focus at all. Safely was. Giving 3-71 to human subjects should in no way imply that 2-73 is failing or vise versa. But the overall MOA seems to be safe and it’s no surprise to see them continue to move forward with 3-71. Painting this news as negative or positive is inherently flawed to some degree but it’s hard to deny that if I knows this was to be news today 5 years ago, I would view it as a positive.
Shows they have confidence in their platform approach and their pipeline in general in my opinion.
3-71 does indeed seem like it could be better than 2-73 - but 2-73 was used first in order to establish safety imo.
Now that the MOA is better understood and it’s safety concerns have been alleviated.. it’s only natural to get this long recipe in the oven as quick as possible. As we all know.. these things take time.. It is their responsibility to shareholders to CONTINUE the pipeline. Plain and simple.
You don’t start giving a drug to healthy adults that is orders of magnitude stronger than the current one being tested unless you probably have some good reason to believe it’s both safe and likely effective... just my honest opinion.
If 2-73 was failing.. it would be counterintuitive to continue or accelerate human trials of 3-71 - would it not?
What I would expect to see if 2-73 was failing, would be more preclinical studies, not clinical.
Looking good here
$AVXL
Awesome! $TSLA
Great news!!!
$AVXL
NEW YORK – July 1, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the first patient was dosed in the EXCELLENCE Phase 2/3 ANAVEX®2-73-RS-003 clinical trial for the treatment of Rett syndrome with ANAVEX®2-73 (blarcamesine).
The Phase 2/3 study will use a convenient once-daily oral liquid ANAVEX®2-73 (blarcamesine) formulation to treat Rett syndrome. Safety and efficacy will be investigated in at least 69 patients over a 12-week treatment period including ANAVEX®2-73-specific precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX®2-73 (blarcamesine) under a voluntary open label extension protocol.
This represents the 3rd ongoing clinical study in Anavex’s Rett Syndrome Program: U.S. RTT (ANAVEX®2-73-RS-001)[1], AVATAR (ANAVEX®2-73-RS-002)[2] and EXCELLENCE (ANAVEX®2-73-RS-003)[3] .
ANAVEX®2-73 (blarcamesine) had previously received Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome.
For parents who wish to learn more about the EXCELLENCE pediatric Phase 2/3 Rett syndrome clinical study, please visit the website, www.rettsyndrometrial.com.
Rett Syndrome Association of Australia (RSAA) will make the necessary bookings and pay for them directly so as not to burden and leave participants and their families out of pocket for major expenses whilst directly participating in the EXCELLENCE trial. Please contact Claude Buda, RSAA President, directly by phone or email for any inquiries:
Claude Buda, RSAA President
Phone: +61 (0)411 089 156
Email: claudebuda@rettaustralia.org.au
“We are delighted to expand the ANAVEX®2-73 (blarcamesine) treatment program for Rett syndrome to include pediatric patients. This is the 3rd ongoing clinical study within the Anavex Rett syndrome program,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “In addition to Rett syndrome, Anavex has ongoing clinical development programs for ANAVEX®2-73 (blarcamesine) for the treatment of Alzheimer’s disease[4] and Parkinson’s disease dementia[5].”
About Rett Syndrome
Rett syndrome is a rare, non-inherited genetic postnatal progressive neurodevelopmental disorder that occurs almost exclusively in girls and leads to severe impairments, affecting nearly every aspect of the child’s life: their ability to speak, walk, eat and even breathe easily. The hallmark of Rett syndrome is near constant repetitive hand movements while awake. It is characterized by normal early growth and development (6 to 18 months) followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures and intellectual disability. There is currently no cure for Rett syndrome and treatment of the disorder is symptomatic. Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties, breathing irregularities and control of seizures through anticonvulsant drugs. Rett syndrome is caused by mutations in the MECP2 gene and strikes all racial and ethnic groups and occurs worldwide in approximately one in every 10,000 to 15,000 live female births.
About ANAVEX®2-73 (blarcamesine)
ANAVEX®2-73 (blarcamesine) activates the Sigma-1 receptor (S1R) protein, which serves as a molecular chaperone and functional modulator involved in restoring homeostasis. In a Phase 2a Alzheimer’s disease (AD) study, ANAVEX®2-73 showed dose dependent improvement in exploratory endpoints of cognition (MMSE) and activities of daily living (ADCS-ADL). The ANAVEX®2-73 Phase 2 Rett syndrome study design includes genomic biomarkers of response identified in the ANAVEX®2-73 Phase 2a AD study. Studies of ANAVEX®2-73 (blarcamesine) in a mouse model of Rett syndrome, carrying a heterozygous Mecp2-null mutation and presenting with neurological impairments that mimic the human disorder, demonstrated improvements at both young ages (~6 weeks) and adulthood (7 months). Chronic oral administration of ANAXEX®2-73 (blarcamesine) led to significant improvements in multiple motor, sensory, and autonomic phenotypes of relevance to Rett syndrome, including motor coordination and balance, acoustic and visual responses, hindlimb clasping (resembling the characteristic hand stereotypies), and episodes of apnea. Notably, these changes were dose related and also evident in animals at an advanced stage of pathology. These experiments were sponsored by Rettsyndrome.org.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors & Media:
Email: ir@anavex.com
[1] ClinicalTrials.gov Identifier: NCT03758924
[2] ClinicalTrials.gov Identifier: NCT03941444
[3] ClinicalTrials.gov Identifier: NCT04304482
[4] ClinicalTrials.gov Identifier: NCT03790709
[5] ClinicalTrials.gov Identifier: NCT03774459
©2020 Anavex Life Sciences | www.anavex.com
It could very well test 3.5-4$ area (at the lowest imo) ... though I highly doubt it
Jmho
Turning point today
$AVXL ... it’s been worth the wait...
Patience And
Perspective
Over a year
...
No
News
...
Back to 3.5 is my guess if 4$ doesn’t hold.
I’ll be adding some more shares if so!
Good luck everyone $AVXL
Looking forward to December 2020 and even more so December 2021
Looking good $AVXL
Nice show of strength
Headed to 5-6$ area soon imo
Good luck everyone
Volume still makes me yawn a bit but.. the trend is good imo
I’m a buyer anywhere under 4$ right now
Nice move!
We aren’t a “penny stock” anymore ($4 = $1 Pre-split)
$AVXL
$avxl
Keep it up
This will be over 1,000$ next year
Jmho
But mark my words!
Read a lot of interesting research the past couple weeks
And still
Anavex (in my opinion) has the best chance at real sustainable disease change
All jmho but I think it worth noting how behind most are compared to Anavex and how most “new” ideas are either outlandish, follow the same failed narrative of old, or propose something that could seriously harm the body in the desperate attempt to get rid of a downstream problem.
Clean the river
And
Start at the top
Jmho
Back under 3$ next week? I hope it gives 3$ a nice test again - then headed to 4$+ and beyond imo
Hang around 4$ area for a week or so - then 5$ should form a new base - Jmho
Good luck everyone $AVXL
5$+
Is my guess
Here comes a bull run IMO
$AVXL
Almost a year and .. no news!? Smh
Nice volume on a Green Day $avxl
Looks to me like the 2.20 area might be our final bottom - Jmho
-
I’m a buyer tomorrow - accumulation mode for me.. great prices and worth taking the risk, in my opinion of course
Good luck everyone $AVXL
Back to 2$ ? Probably